FREMONT, Calif., Dec. 8, 2015 /PRNewswire/ -- DiscoveRx Corporation (www.discoverx.com), a leading global provider of drug discovery products and services, today announced the successful completion of multi-year, kinase-based screening activities for Blueprint Medicines, as well as the extension of the parties' agreement to conduct additional screening activities.
Under the terms of the initial agreement, Blueprint Medicines used DiscoveRx's industry-leading KINOMEscan® high throughput screening platform, comprised of nearly 500 wild-type and disease-relevant mutant kinase assays, to annotate its proprietary library of diverse and novel kinase inhibitors with broad in vitro potency and selectivity data. Under the extended agreement, Blueprint Medicines will continue to use KINOMEscan® to screen new compounds as it expands its library. Blueprint Medicines' annotated library provides high-quality medicinal chemistry starting points that enable quick-starts to its drug discovery programs. Blueprint Medicines maintains sole ownership of all compounds and compound data.
"The ability to characterize the diverse collection of kinase inhibitors in our proprietary compound library provides us with unique insights into the potency and selectivity of a potential drug candidate early in the discovery process, helping us accelerate lead identification," said Tim Guzi, Blueprint Medicines' Vice President of Chemistry. "We look forward to continuing to work with DiscoveRx as we expand our library with additional novel kinase inhibitor scaffolds."
Daniel K. Treiber Ph.D., Vice President of Research of DiscoveRx's KINOMEscan® division stated: "The panel breadth, rapid turnaround times and outstanding data accuracy of our KINOMEscan® platform were key assets in annotating Blueprint Medicine's compound library. We look forward to continuing our work together."
Todd R. Nelson Ph.D., CEO of DiscoveRx stated: "Our successful relationship with Blueprint Medicines serves to further demonstrate the value of our KINOMEscan® platform in generating important data to support our drug discovery partners' lead identification and optimization efforts."
About DiscoveRx Corporation
DiscoveRx® is an innovative company that develops, manufactures, and commercializes reagents, complete cell-based assay kits, profiling and screening services as well as other turnkey solutions for the drug discovery, screening, and life science markets. Our biochemical and cell-based assays enable customers to improve research productivity and effectiveness of their screening, lead optimization and SAR campaigns, thus accelerating the discovery and development of new drugs. Plus, with the addition of the BioMAP® platform of human primary cell systems for phenotypic profiling, DiscoveRx offers a powerful tool to deliver physiologically relevant insights and integrated solutions for all stages of discovery from target and lead discovery to preclinical and beyond.
Logo - http://photos.prnewswire.com/prnh/20130912/SF78575LOGO
Under the terms of the initial agreement, Blueprint Medicines used DiscoveRx's industry-leading KINOMEscan® high throughput screening platform, comprised of nearly 500 wild-type and disease-relevant mutant kinase assays, to annotate its proprietary library of diverse and novel kinase inhibitors with broad in vitro potency and selectivity data. Under the extended agreement, Blueprint Medicines will continue to use KINOMEscan® to screen new compounds as it expands its library. Blueprint Medicines' annotated library provides high-quality medicinal chemistry starting points that enable quick-starts to its drug discovery programs. Blueprint Medicines maintains sole ownership of all compounds and compound data.
"The ability to characterize the diverse collection of kinase inhibitors in our proprietary compound library provides us with unique insights into the potency and selectivity of a potential drug candidate early in the discovery process, helping us accelerate lead identification," said Tim Guzi, Blueprint Medicines' Vice President of Chemistry. "We look forward to continuing to work with DiscoveRx as we expand our library with additional novel kinase inhibitor scaffolds."
Daniel K. Treiber Ph.D., Vice President of Research of DiscoveRx's KINOMEscan® division stated: "The panel breadth, rapid turnaround times and outstanding data accuracy of our KINOMEscan® platform were key assets in annotating Blueprint Medicine's compound library. We look forward to continuing our work together."
Todd R. Nelson Ph.D., CEO of DiscoveRx stated: "Our successful relationship with Blueprint Medicines serves to further demonstrate the value of our KINOMEscan® platform in generating important data to support our drug discovery partners' lead identification and optimization efforts."
About DiscoveRx Corporation
DiscoveRx® is an innovative company that develops, manufactures, and commercializes reagents, complete cell-based assay kits, profiling and screening services as well as other turnkey solutions for the drug discovery, screening, and life science markets. Our biochemical and cell-based assays enable customers to improve research productivity and effectiveness of their screening, lead optimization and SAR campaigns, thus accelerating the discovery and development of new drugs. Plus, with the addition of the BioMAP® platform of human primary cell systems for phenotypic profiling, DiscoveRx offers a powerful tool to deliver physiologically relevant insights and integrated solutions for all stages of discovery from target and lead discovery to preclinical and beyond.
Logo - http://photos.prnewswire.com/prnh/20130912/SF78575LOGO
